KR101729918B1 - １１―（２―피롤리딘―１―일―에톡시）―１４，１９―디옥사―５，７，２６―트리아자―테트라사이클로［１９．３．１．１（２，６）１（８，１２）］헵타코사―１（２５），２（２６），３，５，８，１０，１２（２７）ｊ１６，２１，２３－데카엔 시트르산염 - Google Patents

１１―（２―피롤리딘―１―일―에톡시）―１４，１９―디옥사―５，７，２６―트리아자―테트라사이클로［１９．３．１．１（２，６）１（８，１２）］헵타코사―１（２５），２（２６），３，５，８，１０，１２（２７）ｊ１６，２１，２３－데카엔 시트르산염 Download PDF

Info

Publication number
KR101729918B1
KR101729918B1 KR1020117015738A KR20117015738A KR101729918B1 KR 101729918 B1 KR101729918 B1 KR 101729918B1 KR 1020117015738 A KR1020117015738 A KR 1020117015738A KR 20117015738 A KR20117015738 A KR 20117015738A KR 101729918 B1 KR101729918 B1 KR 101729918B1
Authority
KR
South Korea
Prior art keywords
salt
batch
group
hcl
ray diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117015738A
Other languages
English (en)
Korean (ko)
Other versions
KR20110106344A (ko
Inventor
브라이언 다이막크
쳉 샤 엔젤린 리
안토니 디오다우니아 윌리엄
Original Assignee
씨티아이 바이오파마 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨티아이 바이오파마 코포레이션 filed Critical 씨티아이 바이오파마 코포레이션
Publication of KR20110106344A publication Critical patent/KR20110106344A/ko
Application granted granted Critical
Publication of KR101729918B1 publication Critical patent/KR101729918B1/ko
Assigned to 소비, 아이엔씨. reassignment 소비, 아이엔씨. 권리의 전부이전등록 Assignors: 씨티아이 바이오파마 코포레이션
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
    • C07D201/02—Preparation of lactams
    • C07D201/10—Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
KR1020117015738A 2008-12-11 2009-12-09 １１―（２―피롤리딘―１―일―에톡시）―１４，１９―디옥사―５，７，２６―트리아자―테트라사이클로［１９．３．１．１（２，６）１（８，１２）］헵타코사―１（２５），２（２６），３，５，８，１０，１２（２７）ｊ１６，２１，２３－데카엔 시트르산염 Active KR101729918B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12166808P 2008-12-11 2008-12-11
US61/121,668 2008-12-11
PCT/SG2009/000473 WO2010068181A1 (en) 2008-12-11 2009-12-09 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt

Publications (2)

Publication Number Publication Date
KR20110106344A KR20110106344A (ko) 2011-09-28
KR101729918B1 true KR101729918B1 (ko) 2017-04-25

Family

ID=41666397

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117015738A Active KR101729918B1 (ko) 2008-12-11 2009-12-09 １１―（２―피롤리딘―１―일―에톡시）―１４，１９―디옥사―５，７，２６―트리아자―테트라사이클로［１９．３．１．１（２，６）１（８，１２）］헵타코사―１（２５），２（２６），３，５，８，１０，１２（２７）ｊ１６，２１，２３－데카엔 시트르산염

Country Status (23)

Country Link
US (2) US8980873B2 (https=)
EP (1) EP2376499B1 (https=)
JP (1) JP5669748B2 (https=)
KR (1) KR101729918B1 (https=)
CN (1) CN102282148B (https=)
AR (2) AR074724A1 (https=)
AU (1) AU2009325147B2 (https=)
BR (1) BRPI0922736B1 (https=)
CA (1) CA2746058C (https=)
DK (1) DK2376499T3 (https=)
ES (1) ES2536558T3 (https=)
HR (1) HRP20150428T1 (https=)
IL (3) IL213418A0 (https=)
MX (1) MX2011006206A (https=)
MY (1) MY160005A (https=)
NZ (1) NZ593223A (https=)
PL (1) PL2376499T3 (https=)
PT (1) PT2376499E (https=)
RU (1) RU2527970C2 (https=)
SG (1) SG171907A1 (https=)
TW (1) TWI449705B (https=)
WO (1) WO2010068181A1 (https=)
ZA (1) ZA201104032B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2536276T3 (es) * 2008-12-11 2015-05-22 Cti Biopharma Corp. Sal maleato de 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-deceno
NZ593223A (en) 2008-12-11 2013-08-30 Cell Therapeutics Inc 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1 (2,6).1(8, 12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
JP5925381B2 (ja) 2012-04-13 2016-05-25 ▲連雲▼港金康和信▲薬業▼有限公司Ｌｉａｎｙｕｎｇａｎｇ Ｊｉｎｋａｎｇ Ｈｅｘｉｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 化合物［４−（２−アミノ−１０−メチル−４−オキソ−６，７，８，９−テトラヒドロ−４ａ，７−エピミノピリミド［４，５−ｂ］［１，４］ジアゼピン−５（４Ｈ）−イル）ベンゾイル］−グルタメート及びその製造
CN105061467B (zh) * 2015-08-28 2017-08-25 苏州立新制药有限公司 一种帕克替尼的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058627A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
NZ528209A (en) * 2001-05-14 2004-09-24 Pfizer Prod Inc The citrate salt of 5, 8, 14-triazatetracyclo (10.3.1.02,11.04.9)-hexadeca-2.(11),3,5,7,9-pentaene
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
EP1461040B1 (en) * 2001-11-29 2006-03-15 Pfizer Products Inc. Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
NZ593223A (en) 2008-12-11 2013-08-30 Cell Therapeutics Inc 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1 (2,6).1(8, 12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007058627A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Oxygen linked pyrimidine derivatives

Also Published As

Publication number Publication date
DK2376499T3 (en) 2015-05-04
ZA201104032B (en) 2012-08-29
IL250310A0 (en) 2017-03-30
CN102282148A (zh) 2011-12-14
ES2536558T3 (es) 2015-05-26
BRPI0922736A8 (pt) 2021-11-09
WO2010068181A1 (en) 2010-06-17
PT2376499E (pt) 2015-06-03
US9624242B2 (en) 2017-04-18
JP2012511571A (ja) 2012-05-24
CA2746058C (en) 2016-05-17
TW201028426A (en) 2010-08-01
EP2376499A1 (en) 2011-10-19
BRPI0922736A2 (pt) 2017-10-31
BRPI0922736B1 (pt) 2022-02-22
MX2011006206A (es) 2011-07-20
CN102282148B (zh) 2014-12-24
NZ593223A (en) 2013-08-30
IL213418A0 (en) 2011-07-31
AR074724A1 (es) 2011-02-09
US8980873B2 (en) 2015-03-17
HRP20150428T1 (xx) 2015-06-19
KR20110106344A (ko) 2011-09-28
AR114133A2 (es) 2020-07-22
US20150322084A1 (en) 2015-11-12
EP2376499B1 (en) 2015-02-25
PL2376499T3 (pl) 2015-07-31
JP5669748B2 (ja) 2015-02-12
RU2527970C2 (ru) 2014-09-10
TWI449705B (zh) 2014-08-21
SG171907A1 (en) 2011-07-28
CA2746058A1 (en) 2010-06-17
US20110294831A1 (en) 2011-12-01
RU2011126173A (ru) 2013-01-20
HK1161877A1 (en) 2012-08-10
AU2009325147B2 (en) 2014-08-14
IL289379A (en) 2022-02-01
AU2009325147A1 (en) 2011-06-23
WO2010068181A8 (en) 2011-08-18
MY160005A (en) 2017-02-15

Similar Documents

Publication Publication Date Title
JP7352841B2 (ja) ３－（イミダゾ［１，２－ｂ］ピリダジン－３－イルエチニル）－４－メチル－Ｎ－｛４－［（４－メチルピペラジン－１－イル）メチル］－３－（トリフルオロメチル）フェニル｝ベンズアミドおよびその一塩酸塩の結晶形
KR101729918B1 (ko) １１―（２―피롤리딘―１―일―에톡시）―１４，１９―디옥사―５，７，２６―트리아자―테트라사이클로［１９．３．１．１（２，６）１（８，１２）］헵타코사―１（２５），２（２６），３，５，８，１０，１２（２７）ｊ１６，２１，２３－데카엔 시트르산염
US8987243B2 (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt
CN102762577B (zh) 9e-15-(2-吡咯烷-1-基-乙氧基)-7,12,25-三氧杂-19,21,24-三氮杂-四环[18.3.1.1(2,5).1(14,18)]二十六碳-1(24),2,4,9,14,16,18(26),20,22-壬烯柠檬酸盐
HK1161877B (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
HK1178159B (en) 9e-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza- tetracyclo[18.3.1.1(2,5).1(14)18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20200107

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10